was effective in reducing PIP, particularly in modifying prescribing of proton pump inhibitors, the most commonly occurring PIP nationally.
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INTRODUCTION
Older people tend to have multimorbidity with consequent polypharmacy, making prescribing in this population challenging, with the potential for adverse outcomes including drug-drug interactions and adverse drug events (ADEs). 1, 2 Potentially inappropriate prescribing (PIP) describes a number of suboptimal prescribing practices particularly the use of medicines that introduce a greater risk of ADEs where a safer, as effective alternative is available to treat the same condition. 3, 4 PIP in older people is common across healthcare settings and can result in increased morbidity, ADEs and hospitalisations. 2, 5, 6 In Ireland, 36% of those aged ≥70 years received at least one potentially inappropriate prescription in 2007, with an associated expenditure of over €45 million. 7 PIP in community-dwelling older Irish people is associated with increased ADEs, accident and emergency (A&E) visits, and poorer health related quality of life (HRQOL). 8 Interventions targeting PIP represent an important public health measure, particularly in primary care where the majority of prescribing takes place. There is no one interventional strategy that has proved to be most effective. 9 A number of commentators have argued that a multifaceted intervention, which combines a number of techniques within a single intervention, 10 may be more likely to improve prescribing than any one single intervention. 11, 12 To date, a limited number of multifaceted interventions have been evaluated in primary care to decrease PIP. 13, 14 The purpose of the OPTI-SCRIPT study (OPTImizing PreSCRIbing for Older People in Primary Care, a clusTer randomised controlled trial) was to investigate the effectiveness of a multifaceted intervention in reducing PIP in older people in Irish primary care.
METHODS
A cluster randomised controlled trial (RCT) was conducted in Irish primary care to alter general practitioner (GP) PIP-related prescribing following the CONSORT guidelines. 15 The study protocol and intervention development have been detailed previously. 16, 17 The
Research Ethics Committee of the Irish College of General Practitioners (ICGP) approved the study.
Recruitment and randomisation
GP practices from the Health Research Board (HRB) Centre for Primary Care Research network were invited to participate by email with a follow-up phone call. Practices were eligible if they had at least 80 patients aged ≥ 70 years and were based in greater Dublin.
Consenting practices were instructed to randomly select 50 patients aged ≥ 70 years with capacity to provide informed consent. Prescriptions of these patients were assigned a study ID and sent to the research team where the research pharmacist determined if they had PIP (Appendix 1). 16 Eligible patients were sent study information packs by the GP practice and those wishing to participate returned signed consent forms to the research team.
Baseline data were collected prior to allocation. Practices were allocated to intervention and control by an independent researcher using minimisation (Minimpy 18 ), an allocation method commonly used in cluster RCTs to ensure balanced allocation of important cluster level attributes such as practice size when cluster numbers are small. It was not possible to blind patients or GPs to allocations, however, the outcome assessor was blinded.
Intervention and control groups
The multifaceted intervention involved academic detailing with a pharmacist on how to conduct GP-led medicines review with participating patients; medicines reviews were supported by web-based pharmaceutical treatment algorithms for GPs providing evidencebased alternative treatment options to PIP drugs; and tailored patient information leaflets, (Table 1 and Appendix 2) 16 The intervention was delivered from October 2012 to September 2013. Control practices delivered usual care and received one-off simple patientlevel PIP feedback (Table 1) .
Outcomes
Outcome data were collected upon intervention completion (i.e. point at which all reviews were completed in a practice) at approximately 4-6 months following baseline data collection.
Primary outcomes
Two primary outcomes were used, firstly, the proportion of patients with PIP drugs (a composite measure, i.e. any number of PIP drugs as included in the study to address multiple PIP in individual patients). Secondly, the mean number of PIP drugs per group was investigated. PIP was determined for intervention and control groups from a review of prescriptions by a research pharmacist (Appendix 1).
Secondary outcomes
Secondary outcomes included individual measures of the composite measure, i.e. drugspecific outcomes, including the absolute number of PIP drugs per group of the top five reported nationally: 7 proton pump inhibitor at full therapeutic dosage for >8 weeks, longterm (>3 months) use of non-steroidal anti-inflammatories (NSAIDs), long-term (>1 month) use of long-acting benzodiazepines, therapeutic duplication and tricyclic antidepressants (TCAs) with an opiate or calcium channel blocker. Patient-reported outcomes included the Patients' Beliefs about Medicines Questionnaire (BMQ), 19 and the Well-being Questionnaire (WBQ-12) 20 collected via self completed questionnaires.
Sample size calculation
A sample of at least 22 practices and 220 patients was required, incorporating the effects of cluster randomisation and a 10% loss to follow-up. The calculation was based on both primary outcomes. The calculation for the proportion of participants with PIP was based on demonstrating a clinically relevant 10% absolute reduction (from 100% to 90%) in the proportion of PIP, with 80% power and a statistical significance of 5% (1-sided), between randomised groups. For the mean, the calculation was based on demonstrating a 30% relative reduction in the mean number of potentially inappropriate prescriptions in the intervention group compared to the control group (equivalent to a mean reduction of 1.02 inappropriate prescriptions), with 80% power and a statistical significance of 5% (2-sided). 17 
Analysis
Data analysis was by intention to treat.
Primary outcomes
Separate approaches were used to analyse the two primary outcomes. The proportion of patients with PIP is presented and was analysed using a random effects logistic regression with the individual as the unit of analysis and the practice included as the random effect, to control for the effects of clustering. Baseline covariates (age, gender, baseline number of PIP drugs, baseline number of repeat medications) and minimisation factors (number of GPs, practice location) were included in the model. The mean number of PIP drugs was calculated per group, as specified in the study protocol, and a mean difference calculated using a cluster level t-test. 17 However, preliminary analyses indicated that the data were skewed. The median number of PIP drugs was additionally investigated and skewness was addressed using a random effects Poisson regression, presenting incidence rate ratios (IRRs). Again, the individual was the unit of analysis and the practice was included as the random effect, and baseline covariates and minimisation factors were included. The Bonferroni correction was used to adjust for multiple comparisons.
Secondary outcomes
Random effects logistic regressions were used to test the differences in drug-specific secondary outcomes between intervention and control and random effects multiple regressions were conducted for the patient-reported outcomes.
National contemporaneous comparison group
The control group may have changed their prescribing behaviour due to the reactive effects of being studied (Hawthorne effect) and receiving simple feedback. 21, 22, 23 In anticipation of this, anonymised data from the Primary Care Reimbursement Service (PCRS) pharmacy claims database of dispensed medications (national prescribing database of GP and pharmacy claims) 24 PIP was assessed using 28 criteria included in this study, 16 (six of the PIP criteria could not be applied as the PCRS data lacked the detailed information needed).
From these figures, crude odds ratios (ORs) were calculated, comparing the OPTI-SCRIPT intervention and control groups to the national PCRS comparator. Figure 1 displays the flow of participants through the RCT. In total 21 GP practices and 196 patients were recruited. All GP practices and 190 (97%) patients were followed up on intervention completion. Practices and patients were similar at baseline but the control group were situated in more socioeconomically deprived areas (Table 2 ). Proton pump inhibitors at maximum therapeutic dosage > 8 weeks was the most frequently occurring PIP in both groups (Table 3) .
RESULTS

Primary outcomes
Upon intervention completion, the proportion of patients with PIP drugs was 0.52 in intervention compared to 0.77 in control. Participants in the intervention group had significantly lower odds of having PIP than those in the control group (adjusted OR 0.32, 95% confidence interval (CI) 0.15 to 0.70, P=0.02) ( Table 4 ).
The mean number of PIP drugs in the intervention group was 0.70, compared to 1.18 in the control group (P=0.02). The median was 1 in both intervention and control.
Investigating the number of PIP drugs per person using Poisson regression, patients in the intervention group were estimated to have 29% less PIP drugs than patients in the control group, but this was not significant at the 5% level (IRR 0.71, 95% CI 0.50 to 1.02, P=0.49) (Table 4) .
Secondary outcomes
Drug specific outcomes
At intervention completion, participants in the intervention group had significantly lower odds of having a potentially inappropriate proton pump inhibitor compared to those in the control group (adjusted OR 0.30, 95% CI 0.14 to 0.68, P=0.04). No statistically significant differences were found for other drug-specific outcomes (Table 5 ). In the intervention group, 50% of potentially inappropriate proton pump inhibitors were amended by dose reduction to maintenance level, 20% were stopped completely, 11% were switched to an alternative (e.g. H2 antagonist) and 20% were unaltered.
Patient reported outcomes
For the patient reported outcomes of well-being and beliefs about medication, no statistically significant differences were found after completion of the intervention (Table 5) .
National contemporaneous comparison group
Participants in the OPTI-SCRIPT intervention group had lower odds of having PIP compared to those in the national comparator group (crude OR 0.4, 95% CI 0.3 to 0.6) and were more likely to have a decrease in the number of PIP drugs, than the national comparator group (crude OR 2.5, 95% CI 1.8 to 4.0) ( Table 6 ).
DISCUSSION
The OPTI-SCRIPT intervention was effective in reducing PIP. However, this effect was mediated principally through reducing prescriptions of proton pump inhibitors at maximal dose, the most commonly encountered study PIP.
Previous studies aimed at reducing PIP have been focused in hospital and nursing home settings. [25] [26] [27] A limited number of RCTs to reduce PIP specifically in primary care have been conducted. Of those interventions that have been evaluated, single interventions such as computerised decision support systems (CDSSs), educational interventions and multidisciplinary teams have produced inconsistent effects. 2, 28, 29 Multifaceted interventions may be more likely to improve prescribing than single interventions. 11, 12 Our results are consistent with two separate RCTs published since the start of the OPTI-SCRIPT study in finding a multifaceted intervention to be effective. 13, 14 Rognstad et al. found peer academic detailing, delivered at continuing medical education (CME) meetings, with mailed prescriber feedback, produced a 10% (95% CI 5.9 to 15.0) reduction in PIP in the Rx-PAD study. 14,30 Bregnhoj et al. found interactive educational meetings and feedback resulted in a 5-point (95% CI -7.3 to -2.6) improvement in the medication appropriateness index (MAI) score. 13 Differences in effect sizes reported between these studies and the OPTI-SCRIPT findings may arise from a number of factors including differences in the criteria used to assess PIP, the duration of follow-up and the included patients.
An important difference may also be the intensity of the intervention. OPTI-SCRIPT was more intensive, delivering academic detailing face-to-face, rather than a group setting.
During the medication reviews, GPs were provided directly with patient-specific lists of PIP drugs and advice on medication changes via the web-based pharmaceutical treatment algorithms, feasibly, having a larger effect size as it encouraged an immediate action to be taken rather than providing educational support or information.
Changes in prescribing of particular drugs can be responsible for the overall effectiveness of interventions. 31 The OPTI-SCRIPT intervention primarily impacted on proton pump inhibitors prescribing which was highly prevalent at baseline (60%). No impact on therapeutic duplication or benzodiazepine use was found. This is likely due to the small numbers of patients exposed to these PIP drugs. However, this may also reflect the different challenges of modifying medicines as opposed to altering dosage regimes, particularly with benzodiazepines, whose tolerance levels result in interventions to improve prescribing having varying success. 32 There is a concern that discontinuation of benzodiazepines in this population may produce more harm than benefit and patients may be reluctant discontinue. 33, 34 OPTI-SCRIPT GPs, may have been more comfortable altering proton pump inhibitors than benzodiazepines. Based on the low number of benzodiazepines in this study,
we cannot be certain that the OPTI-SCRIPT intervention would be effective in reducing prescribing of these medications.
The OPTI-SCRIPT intervention was not found to impact on patients' sense of well-being and beliefs about medicine. The sample size may have been too small and the follow-up period too short to detect a difference in patient reported outcomes, a common criticism of prescribing interventions. 28 It is possible that beliefs about medicines may have been more likely to change than patients' well-being given the short follow-up period, however, evidence indicates that beliefs about medicines remain stable over time, irrespective of changes in health status. 35 Overall, these results suggest that modifications in proton pump inhibitors dosage do not appear to affect patient's sense of well-being or concerns.
Strengths and limitations
Strengths of this study include a rigorous design of a clinically relevant intervention, 16 high retention rates (primarily due to the nature of the outcome data and the short follow-up period), completeness of the prescription data and being conducted in a primary care setting using existing resources. Selection bias was minimised by collecting baseline data prior to minimisation, which was carried out by an independent third party. Owing to the nature of the intervention, it was not possible to blind patients or GPs to allocations, however, the outcome assessor was blinded to allocation, The intervention was effective at decreasing the most prevalent PIP (proton pump inhibitors) in this study. The more frequent an outcome is, the greater the potential the OR will over or under estimate the relative risk (RR). Using methods proposed by Zhang et al 36 , we explored this and found little difference between the OR (0.32) and the RR (0.38), increasing confidence in the study findings.
While the analysis of a non-randomised comparison group (PCRS data) provided a national context to the study, findings revealed no notable difference overall in prescribing behaviour by the control group compared to prescribing nationally, this is a non-randomised group and is therefore subject to confounding.
The external validity of this study may have limitations. GP recruitment was modest at 32%, comparing favourably to similar PIP related RCTs 13 but smaller than reported in other primary care studies. 37 When compared to a national sample of practices, 38 study practices had, on average, more GPs and public patients so may not be representative of practices nationally. However, the last available national data on GPs was from 2005 so may be somewhat out of date. 38 
Implications for practice and directions for future study
The reduction in PIP in the OPTI-SCRIPT study may have important clinical and economic implications. Almost half of the intervention group were no longer exposed to PIP at intervention completion. While it cannot be assumed that a change in PIP necessitates a change in health outcomes, 39, 40 reducing PIP potentially may decrease adverse outcomes such as ADEs and hospitalisations in older patients. 5 As the OPTI-SCRIPT study effect size was largely driven by proton pump inhibitor prescribing, the intervention may attenuate the risks associated with these drugs such as hip fractures and community acquired pneumonia. 41, 42 Reducing PIP related to proton pump inhibitor prescribing may also contribute to significant savings as an estimated €22 million was spent on potentially inappropriate proton pump inhibitors in 2007. 43 Based on the positive findings presented here, further modelling of the intervention components is planned to determine the effectiveness of the OPTI-SCRIPT intervention long term and the potential impact it may have on cases of PIP other than for proton pump inhibitor prescribing.
PIP is an important public health concern that can result in increased morbidity, adverse drug events, hospitalisation and expenditure. 2, 7 This study shows that the OPTI-SCRIPT intervention reduced PIP, primarily through a reduction in proton pump inhibitor prescribing, in a way that this is acceptable to both GPs and their patients. Tailoring of the intervention to impact more specifically on different cases of PIP is planned. Tables  Table 1 Summary 
Control
Control practices delivered usual care. Usual care for public general medical services (GMS) patients allows GPs to give a prescription on a monthly or three monthly basis.
Control practices received simple patient-level PIP postal feedback in the form of a list summarizing the medication class to which the individual patient's potentially inappropriate medication belonged.
Control practices did not receive an academic detailing visit or were not prompted to carry out medicines review with the individual patients. Abbreviations: GMS (general medical services); PIP (potentially inappropriate prescribing) 
